Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts
|
|
- Susan Greer
- 5 years ago
- Views:
Transcription
1 Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at Disclaimer: The information contained in this document is intended only for use during the presentation and should not be disseminated or distributed to parties outside the presentation. DBS Bank accepts no liability whatsoever with respect to the use of this document or its contents.
2 First quarter net profit at $ 412 million ($ million) 1Q 1Q YoY % 4Q QoQ % change 2004 change Net profit excluding (30%) 426 (3%) goodwill amortization Net profit on GAAP (15%) % basis* * FRS 103 accounting change for goodwill amortization not retroactively applied to 2004 reported results 2
3 Nine consecutive quarters of loan growth; net interest income highest in ten quarters Customer loans* $ 71 billion 22% $ 13 billion Net interest income $ 664 million * Exclude DBS Thai Danu Bank 3
4 Sustained growth in customer franchise across the region Net profit Consumer, SME $ 233 million 18% Consumer $ 150 million 25% SME $ 83 million 6% Consumer, SME combined accounted for 57% of DBS total net profit for the quarter 4
5 Strong asset quality, balance sheet supports DBS growth Asset quality one of the best among Asian banks NPL rate of 2.4% Provision coverage of 90% Strong balance sheet Moody s Aa2 credit rating among highest of banks competing in Asia-Pacific Tier 1 ratio: 10.9% Overall CAR: 15.3% 5
6 Delivering sustainable and progressively increasing dividends Instituted quarterly dividend programme First Quarter 2005 dividend set at 11 cents per share 6
7 Well-positioned to achieve further growth, deliver higher returns to shareholders More balanced and diversified business mix Strengthened customer franchise Up-to-date risk management practices, technology and operations platform Continue to extend business model to new geographies, grow our share in existing markets 7
8 Operating profits improve 16% on quarter from revenue growth and lower expenses (S$m) 1Q Q 2004 % change 4Q 2004 % change Net interest income Non-interest income (36) Operating income 1,072 1,270 (16) 1,027 4 Staff costs Other operating expenses (5) 282 (13) Operating expenses (1) 541 (6) Operating profit (26) Provisions/(write-backs) (31) nm Net profit before goodwill (30) 426 (3) Goodwill amortisation (100) 110 (100) Net profit (15)
9 Key ratios generally unchanged on quarter (%) 1Q Q Q 2004 Net interest margin Non-interest income/total income Cost/income ROE Loans/deposits Loan + non-trading debt securities/ deposits NPL ratio
10 Net interest income highest in ten quarters, margins steady (S$m) Net interest margin (%) 2,645 2,375 2, Q 2Q 3Q 4Q 1Q
11 Loans expand 14% on year to record (S$m) DTDB loans 2% 71,060 2,915 2% 2,915 4% 3,275 3% 4% 69,664 61,420 62,429 65,053 67,221 Dec 2003 Mar 2004 Jun 2004 Sep 2004 Dec 2004 Mar
12 Fee income from annuity businesses remains steady (S$m) , a 548 a 1, ,883 1, b b b Q 2Q 3Q 4Q 1Q b 2004 Fee income Dividend & rental Other income Non-interest income / total income (%) 2005 (a) Excluding one-time gains of $96m (b) Excluding one-time gains of $497m 12
13 Wealth management sales improve, revenues rise 16% on quarter (S$m) 9,006 9,242 Structured deposits Bancassurance Unit trusts 7,227 5, ,766 2,545 1,732 2,093 2, ,526 1, ,157 2, , ,578 1, Q 2Q 3Q 4Q 1Q Sales (all products) S pore 4,162 3,874 1, , HK 4,844 5,368 1,522 1,175 1,517 1,154 1,102 Fees (unit trusts and bancassurance only) S pore + HK
14 Revenues rebound on quarter, customer businesses resilient (S$m) 1Q Q 2004 Change 4Q 2004 Change Consumer Banking Enterprise Banking (4) Corporate and Investment Banking (2) Global Financial Markets (239) Central Treasury Unit (62) 85 (39) Central Operations Total 1,072 1,270 (198) 1,
15 Operating costs kept under control (S$m) 1, a 45 1, , b b 46 Cost/Income (%) Q 2Q 3Q 4Q 1Q Annualised cost / average assets (%) Headcount c 12,035 12,144 11,454 12,173 10,838 11,083 11,454 11,649 Staff costs (S$m) (a) Excluding one-time gains of $96m (b) Excluding one-time gains of $497m (c) At period end 15
16 Hong Kong s net profit 27% lower on year (S$m) 1Q 1Q % 4Q % change 2004 change Net interest income (9) 205 (2) Non-interest income (29) 124 (20) Operating income (16) 329 (9) Operating expenses (4) Op profit before provisions (31) 171 (13) Provisions 7 25 (72) 23 (70) Net profit (27) 129 (6) Exchange rate at HK$1 to S$ for all periods. Based on Singapore GAAP 16
17 Key Hong Kong ratios continue to support group (%) 1Q Q Q 2004 Net interest margin Non-interest income/total income Cost/income ROA Loans/deposits
18 Regional revenues continue to grow at faster pace Amount (S$m) 1Q Q 2005 YoY change (%) Revenues Region and rest of world a Hong Kong Singapore Total , , (18) (15) (13) Net profit b Region and rest of world a (59) Hong Kong (26) Singapore (27) Total (40) (a) Excluding DTDB in all periods (b) Excluding goodwill amortisation 18
19 NPL rate edges down to 2.4% (S$m) Substandard Doubtful Loss NPL rate (%) ,224 3,780 3, % 73% 1,919 75% 2,182 1,934 1,919 1, % 20% 5% 22% 71% 9% 20% 6% 19% 72% 9% 19% 70% 9% 21% 71% 9% 20% 72% 9% 19% Mar Jun Sep Dec Mar
20 Non-performing loans stable as additions offset recoveries and write-offs (S$m) 1Q Q Q 2004 NPLs at start of period 1,919 1,934 3,780 New NPLs Net recoveries of existing NPLs (135) (261) (396) Write-offs (41) (79) (175) NPLs at end of period 1,928 1,919 3,359 20
21 Specific provision charges remain low (S$m) 1Q Q Q 2004 Add charges for New NPLs Existing NPLs Subtract charges for Upgrading Settlements Recoveries Total SP charges
22 Provision coverage improves to 90% (S$m) GP SP ,500 2,387 2, ,064 1,701 1,819 1,752 1,701 1,736 1,072 1,015 1,025 1,037 1,015 1,036 1,511 1,323 1, Mar Jun Sep Dec Mar Coverage ratios (%) SP+GP / Unsec NPAs SP+GP / NPAs
23 Tier-1 CAR trimmed as RWA expands in 1Q (%) Tier-2 CAR Tier-1 CAR Mar Jun Sep Dec Mar (S$bn) Tier-1 capital RWA capital ratios based on MAS framework. Earlier periods based on BIS guidelines 23
24 Quarterly dividend rate of 11 cents (Cents) Final Interim Quarterly Q
25 Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at Disclaimer: The information contained in this document is intended only for use during the presentation and should not be disseminated or distributed to parties outside the presentation. DBS Bank accepts no liability whatsoever with respect to the use of this document or its contents.
Singapore Exchange Limited 1Q FY2009 Financial Results
Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1 1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008
More information1Q2017 法人說明會 Jun. 9, 2017
1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic
More informationMay 6, 2008 First Quarter 2008 Results
SWEUB2227319CMDV7 May 6, 28 First Quarter 28 Results 1Q 28: Improved results in a challenging environment Page 2 Strong loan growth at 34.2% yoy Accelerated deposit growth at 31% yoy; improved loans /
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationHong Leong Bank Berhad (97141 X) A Member of the Hong Leong Group. A Member of the Hong Leong Group ANNUAL REPORT 2008
Hong Leong Bank Berhad (97141 X) Hong Leong Bank Berhad (97141 X) A Member of the Hong Leong Group A Member of the Hong Leong Group ANNUAL REPORT 2008 Our Corporate Vision An Outstanding Financial Services
More informationCENTRALE. Monetary. compared. domestic. million.
CENTRALE BANK VAN ARUBAA Statistical News Release Second Quarter 2012 Date: November 7, 2012 Monetary and financial developments Money and credit In the second quarterr of 2012, the money supply decreased
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationBancAnalysts Association of Boston Conference Presentation. November 3, 2017
BancAnalysts Association of Boston Conference Presentation November 3, 2017 Disclaimer This presentation contains forward- looking statements within the meaning of the Private Securities Litigation Reform
More informationGroup financial results for the first quarter 2008
Helmut Perlet, Member of the Board of Management Group financial results for the first quarter 2008 Journalists Conference Call May 9th, 2008 Group: robust earnings in stormy weather (EUR mn) Quarterly
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationFINANCIAL RESULTS 1H 2016 Growth in key volumes and core revenues
FINANCIAL RESULTS 1H 2016 Growth in key volumes and core revenues Warsaw, 03.08.2016 Disclaimer This presentation (the Presentation ) has been prepared by Bank Polska Kasa Opieki Spółka Akcyjna ( Bank
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationFINANCIAL RESULTS 1H 2015 Core revenues supporting 2015 plan delivery
FINANCIAL RESULTS 1H 2015 Core revenues supporting 2015 plan delivery Warsaw, 04.08.2015 Disclaimer This presentation (the Presentation ) has been prepared by Bank Polska Kasa Opieki Spółka Akcyjna ( Bank
More informationFY2016 1H Results. Cookpad Inc.
FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More informationWelcome to LG Electronics
Welcome to LG Electronics April 21, 2004 As a note, this presentation has been prepared based on internal audited figures and final figures may change due to the results of independent auditors review.
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More information1Q16 FINANCIAL RESULTS
1Q16 FINANCIAL RESULTS Towards the execution of our plan Warsaw, 10 May 2016 Disclaimer This presentation (the Presentation ) has been prepared by Bank Polska Kasa Opieki Spółka Akcyjna ( Bank ) for the
More informationWoongjin Coway. 1Q 12 IR Presentation
Woongjin Coway 1Q 12 IR Presentation Disclaimer This presentation contains historical information of the company which should not be regarded as an indication of the future performance or results. This
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationASL MARINE. DBS Vickers Pulse of Asia Roadshow 10 January 2012
ASL MARINE DBS Vickers Pulse of Asia Roadshow 10 January 2012 Presentation Outline Group Overview 1Q FY2012 Financial Review (3 months ended 30 September 2011) Operations Review - Shipbuilding - Shiprepair
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationSingapore Press Holdings. 1Q FY12 Financial Results 10 January 2012
Singapore Press Holdings 1Q FY12 Financial Results 10 January 2012 Group 1Q FY12 financial highlights 1Q FY12 S$ 000 1Q FY11 S$ 000 Change % Operating Revenue 332,406 318,717 4.3 Operating Profit # 121,230
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK. Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011
ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011 STRUCTURE 1. National economy 2. International economy 3. Outlook 2 CENTRALE
More informationCochlear Limited Results for the half year ended 31 December 2007
Cochlear Limited Results for the half year ended 31 December 2007 Chris Roberts Chief Executive Officer Neville Mitchell Chief Financial Officer Cochlear Overview Medical device company (~26yr): global
More informationCorporate Presentation October New growth cycle and value innovation
Corporate Presentation October 2017 New growth cycle and value innovation Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Strategic competitive advantages 4 Financial and Operational
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More information1Q 2014 Earnings Release
1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains
More informationSupplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016
Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic
More information1Q 2015 Results A Positive Start to 2015
1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results
More informationInvestor Presentation
Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationInterim Report 1 January September 2017
2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights
More informationFor personal use only
Cedar Woods Properties Limited EUROZ INVESTOR CONFERENCE 14 March 2017 Cedar Woods strategy Cedar Woods Presentation 2 To grow and develop our national project portfolio, diversified by: geography product
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationSummary Statement of Financial Position (consolidated)
2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationPortfolio Strategy Group
PSG's Weekly Chart Perspective Portfolio Strategy Group Report Date: Monday, September 27, 21 Daily Close UST 1 Year CMT 5 Year History 5. 4.5 4. 3.5 3. 2.5 2. US Recession Sep-5 Dec-5 Mar-6 Jun-6 Sep-6
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More informationPortfolio Strategy Group
PSG's Weekly Chart Perspective Portfolio Strategy Group Report Date: Monday, November 15, 21 Daily Close UST 1 Year CMT 5 Year History 5. 4.5 4. 3.5 3. 2.5 2. US Recession Nov-5 Feb-6 May-6 Aug-6 Nov-6
More informationGroup 1Q FY13 financial highlights
Singapore Press Holdings 1Q FY13 Financial Results 14 January 2013 Group 1Q FY13 financial highlights 1Q FY13 S$ 000 1Q FY12 S$ 000 Change % Operating Revenue 322,092 332,406 (3.1) Operating Profit # 109,371
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK
Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive
More informationRAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance
Contact: Investor Relations: Morris Moore (336) 741-3116 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2013-10 RAI: Strong key-brands performance
More informationPRICE DEMERS & CO. Barristers, Solicitors & Notaries Public
PRICE DEMERS & CO. Barristers, Solicitors & Notaries Public Incorporation of BVI Business Companies under the BVI Business Companies Act, 2004 1. Introduction The following is a brief summary of the main
More informationWntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should
More informationPRESENTATION ON 2017 THIRD QUARTERLY RESULTS
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness
More informationFisher & Paykel Healthcare
Fisher & Paykel Healthcare Deutsche Bank / Craigs New Zealand Corporate Day 1 Sydney March 2014 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated
More informationQ Investor Kit January December 2015
Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local
More informationSmall-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK
Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final
More informationChina Insulin Industry Report, Jan. 2011
China Insulin Industry Report, 2010 Jan. 2011 This report analyzes the status, competition pattern and development direction of the insulin industry Focuses on the operation and development prospect of
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationMICROCAP LEADERSHIP SUMMIT
MICROCAP LEADERSHIP SUMMIT WESTIN CHICAGO NORTHWEST HOTEL ITASCA, IL SEPTEMBER 23, 2016 SAFE HARBOR STATEMENT This presentation may be deemed to contain certain forward-looking statements with respect
More informationEUROZ INVESTOR CONFERENCE
Cedar Woods Properties Limited EUROZ INVESTOR CONFERENCE 14 March 2017 Cedar Woods strategy Cedar Woods Presentation 2 To grow and develop our national project portfolio, diversified by: geography product
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationCorporate Presentation 1Q18. New growth cycle and value innovation
Corporate Presentation 1Q18 New growth cycle and value innovation Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Sustainability 4 Strategic competitive advantages 5 Financial
More informationDainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement
For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More informationFor personal use only
FY2015 Half Year Results Presentation 6 months ended 30 September 2014 24 28 November 2014 1 First half result highlights H1 FY15 (6 months to 30 September 2014) PCP CC 1 Operating profit +8% +64% RAC
More informationHONG LEONG TOP YIELD ACCOUNT TERMS & CONDITIONS ( T&Cs )
Last updated on 30 May 2018 HONG LEONG TOP YIELD ACCOUNT TERMS & CONDITIONS ( T&Cs ) These terms and conditions are to be read together as a whole with the General Terms and Conditions of Accounts for
More information6.00% CAP Rate $5,600,000. DeerfieldPartners. John Giordani Art Griffith (415) Actual Store
Actual Store Low Price & Great Value $5,6, 6.% CAP Rate Open & paying rent--available for immediate sale Lower price point and great value Offered free & clear; loans available today with as little as
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationONO PHARMACEUTICAL CO., LTD.
ONO PHARMACEUTICAL CO., LTD. February 4, 2005 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2005
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More informationFor personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationQ2 INVESTOR KIT JANUARY-JUNE 2011
Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist
More informationONO PHARMACEUTICAL CO., LTD.
ONO PHARMACEUTICAL CO., LTD. February 6, 2006 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2006
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More information22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
More informationM e d i a s e t G r o u p
M e d i a s e t G r o u p 11 th May 2004 2004 First Quarter Results M e d i a s e t G r o u p BROADCASTING MEDIASET 2004 1Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0%
More information2010 First Quarter Results Presentation. 11 th May 2010
2010 First Quarter Results Presentation 11 th May 2010 1 Broadcasting 2 ITALY TV Consumption trend (2003-2010) Average Daily minutes 271 273 270 270 Individuals 269 266 255 250 251 245 251 256 245 244
More informationThird Quarter Results to September 30, 2009
Third Quarter Results to September 30, 2009 Shire plc October 30, 2009 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700
More informationAnnual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors
Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, 2014 András Tövisi Chairman of the Board of Directors Philip Morris ČR a.s. Annual General Meeting of Shareholders 2014
More informationAltria Group Inc. Ticker: MO
Altria Group Inc. Ticker: MO Business Description Altria Group Inc. through its subsidiaries manufactures and sells cigarettes, other tobacco products, machine-made large cigars and pipe tobacco. It also
More informationQUALITAS MEDICAL GROUP LIMITED. CORPORATE PRESENTATION January 2010
QUALITAS MEDICAL GROUP LIMITED CORPORATE PRESENTATION January 2010 Contents Our Business Corporate Developments Growth Strategies Financial Highlights Summary Business Overview Who We Are Established in
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationartnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016
Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 for Table of Contents General Information and Business Activities Economic Development
More informationBVI Limited Partnership Hedge Funds: Calling Japan
BERMUDA BRITISH VIRGIN ISLANDS CAYMAN ISLANDS CYPRUS DUBAI HONG KONG LONDON MAURITIUS MOSCOW SÃO PAULO SINGAPORE conyersdill.com June 2012 BVI Limited Partnership Hedge Funds: Calling Japan Structuring
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More information